Department of Computer and Information Sciences, University of Strathclyde, Glasgow, United Kingdom.
Department of Psychology, University of Strathclyde, Glasgow, United Kingdom.
JMIR Res Protoc. 2024 May 31;13:e56888. doi: 10.2196/56888.
Cancer-related cognitive impairment (CRCI) is commonly experienced by patients with cancer during treatment, and 35% of patients experience cognitive impairment after treatment completion. Impairments in memory, attention, executive functioning, and information processing speed are most reported and often negatively impact daily functioning and quality of life (QoL). Despite the large scale of reports, this adverse side effect is underinvestigated across common cancer types, and there is a lack of insight into the CRCI experience.
This qualitative synthesis aims to explore the evidence in relation to the experience of CRCI across common cancers. It also aims to understand the prevalence of CRCI across various cancer types, cognitive domains, and its impact on QoL and functional ability.
A comprehensive search of databases, including PubMed, American Psychological Association PsycINFO, CINAHL, and Scopus, will be conducted. A total of 2 independent reviewers will screen titles and abstracts for inclusion, followed by full-text screening. A third reviewer will resolve any arising conflicts in the process of data screening and inclusion. Subsequently, data extraction and quality assessment using the Critical Appraisal Skills Programme (CASP) tool will be conducted. The results will be analyzed using thematic analysis.
This review is part of a PhD program funded in January 2023. The review commenced in June 2023, and data analysis is currently in progress. The qualitative synthesis will explore the experiences of CRCI across common cancers. The included studies are expected to report on numerous cancer types such as breast cancer, prostate cancer, leukemia, and lung cancer. The included study types are most likely to be interviews, focus groups, and surveys with qualitative components.
This protocol highlights the need for a qualitative synthesis that will explore the experience of CRCI across common cancer types. It will provide valuable insight into the lived experience of CRCI and the cognitive domains that may be disproportionately affected. There is a growing demand for further management interventions and clinically tested treatments of CRCI and the qualitative exploration of patient experience is crucial for their development. This qualitative synthesis will inform future developments and will contribute to improving QoL after cancer.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/56888.
癌症相关认知障碍（CRCI）是癌症患者在治疗过程中常见的问题，35%的患者在治疗完成后会出现认知障碍。记忆、注意力、执行功能和信息处理速度受损是最常见的报告，并且经常对日常功能和生活质量（QoL）产生负面影响。尽管报告数量庞大，但这种不良反应在常见癌症类型中研究不足，对 CRCI 的体验也缺乏了解。
本次定性综合分析旨在探讨常见癌症中与 CRCI 相关的证据。它还旨在了解各种癌症类型、认知领域的 CRCI 患病率，及其对 QoL 和功能能力的影响。
将对包括 PubMed、美国心理学会 PsycINFO、CINAHL 和 Scopus 在内的数据库进行全面检索。将由 2 位独立审查员筛选标题和摘要是否符合纳入标准，然后进行全文筛选。在数据筛选和纳入过程中，第三位审查员将解决任何出现的争议。随后，将使用批判性评价技能计划（CASP）工具进行数据提取和质量评估。结果将使用主题分析进行分析。
这是一项于 2023 年 1 月获得博士项目资助的综述的一部分。综述于 2023 年 6 月开始，目前正在进行数据分析。定性综合分析将探讨常见癌症中的 CRCI 体验。预计纳入的研究将报告许多癌症类型，如乳腺癌、前列腺癌、白血病和肺癌。纳入的研究类型很可能是访谈、焦点小组和调查，其中包括定性部分。
该方案强调需要进行定性综合分析，以探讨常见癌症类型中的 CRCI 体验。它将为 CRCI 的生活体验和可能受到不成比例影响的认知领域提供宝贵的见解。人们对 CRCI 的进一步管理干预和临床测试治疗的需求不断增长，对患者体验的定性探索对于其发展至关重要。本次定性综合分析将为未来的发展提供信息，并有助于提高癌症后的生活质量。
国际注册报告标识符（IRRID）：DERR1-10.2196/56888。
